# Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

> clinical trial · VERIFIED · 2026-07-22

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Endometrial Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: Endometrial Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT05256225

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.